bibliographic resource 334709 [br/334709]
https://w3id.org/oc/corpus/br/334709

is a
title
  • A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
subtitle
  • Bortezomib with or without Siltuximab in Multiple Myeloma
publication date
  • 2014-01-01
contributor
format
identifier
part of